{"product_id":"irene-pyrotinib","title":"Irene (Pyrotinib)","description":"\u003ch2\u003eAbout Pyrotinib\u003c\/h2\u003e\u003cp\u003eIrene (Pyrotinib) sold under the brand name 艾瑞妮 in china, Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. \u003c\/p\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eBased on this phase II study, pyrotinib in combination with capecitabine received its first conditional approval in China for the treatment of HER2-positive, advanced or metastatic breast cancer previously exposed to anthracycline or taxane chemotherapy. \u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eDepending on the indication, pyrotinib is taken orally at a standard dose of \u003cb\u003e400 mg\/day\u003c\/b\u003e. Dosage adjustments, combination, or non-combination of any antineoplastic agents are considered according to the physician's decision-making, the patient's previous treatment regimen, and the patient's own circumstances and wishes.\u003c\/p\u003e","brand":"Jiangsu Hengrui Medicine, China","offers":[{"title":"Default Title","offer_id":44797953572907,"sku":"RL2320241030400","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2788.png?v=1787022206","url":"https:\/\/xomeds.com\/products\/irene-pyrotinib","provider":"XOMEDS","version":"1.0","type":"link"}